Lorraine A. Lebel

4.2k citations

42 papers · 2.6k indexed · 1 hit paper · h-index 20

Molecular Biology top 5%
Cellular and Molecular Neuroscience top 2%
Organic Chemistry top 5%
Pharmacology top 2%
Psychiatry and Mental health top 5%

Co-authors: Harry Howard B. Kenneth Koe Anne W. Schmidt Stevin H. Zorn David W. Schulz Ronald G. Browne Patricia A. Seymour Reinhard Sarges
Topics: Receptor Mechanisms and Signaling (19 papers)Neuroscience and Neuropharmacology Research (13 papers)Synthesis and Biological Evaluation (11 papers)
Cited by: Cellular and Molecular Neuroscience Pharmacology Biological Psychiatry
Journals: Journal of Medicinal Chemistry Journal of Neurochemistry Journal of Pharmacology and Experimental Therapeutics
Partner nations: United States Poland United Kingdom

In The Last Decade

Lorraine A. Lebel

41 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants

1990 358 citations Reinhard Sarges, Harry Howard et al. Journal of Medicinal Chemistry profile →

Peers

Countries citing papers authored by Lorraine A. Lebel

Since Specialization

Citations

This map shows the geographic impact of Lorraine A. Lebel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lorraine A. Lebel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lorraine A. Lebel more than expected).

Fields of papers citing papers by Lorraine A. Lebel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lorraine A. Lebel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lorraine A. Lebel. The network helps show where Lorraine A. Lebel may publish in the future.

Co-authorship network of co-authors of Lorraine A. Lebel

This figure shows the co-authorship network connecting the top 25 collaborators of Lorraine A. Lebel. A scholar is included among the top collaborators of Lorraine A. Lebel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lorraine A. Lebel. Lorraine A. Lebel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The discovery of a structurally novel class of inhibitors of the type 1 glycine transporter 2009 ·Bioorganic & Medicinal Chemistry Letters ·John Lowe,Xinjun Hou,Christopher Schmidt,F. David Tingley,(unknown),(unknown),Shari L. DeNinno,Mark A. Sanner,Karen Ward,Lorraine A. Lebel,(unknown),James J. Valentine	25
2	Deconstructing cytisine: The syntheses of (±)-cyfusine and (±)-cyclopropylcyfusine, fused ring analogs of cytisine 2008 ·Bioorganic & Medicinal Chemistry Letters ·Daniel Yohannes,(unknown),Lorraine A. Lebel,Carol B. Fox,Brian T. O’Neill	17
3	Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia 2008 ·Journal of Pharmacology and Experimental Therapeutics ·C J Schmidt,Douglas S. Chapin,(unknown),Michael L. Corman,Mihály Hajós,John F. Harms,William E. Hoffman,Lorraine A. Lebel,Sheryl A. McCarthy,(unknown),(unknown),Mark J. Majchrzak,Andres D. Ramirez,Karl T. Schmidt,P A Seymour,Judith A. Siuciak,F. David Tingley,Robert D. Williams,Patrick R. Verhoest,Frank S. Menniti	238
4	Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid 2006 ·Neuropharmacology ·Hans Rollema,Leslie K. Chambers,J.W. Coe,John R. Glowa,Raymond S Hurst,Lorraine A. Lebel,Yi Lu,Robert S. Mansbach,Robert J. Mather,(unknown),Steven B. Sands,Eric Schaeffer,David W. Schulz,F. David Tingley,Kathryn Williams	446
5	Inhibition of the striatum-enriched phosphodiesterase PDE10A: A novel approach to the treatment of psychosis 2006 ·Neuropharmacology ·Judith A. Siuciak,Douglas S. Chapin,John F. Harms,Lorraine A. Lebel,Sheryl A. McCarthy,Leslie K. Chambers,Alka Shrikhande,Stephen K.-F. Wong,Frank S. Menniti,Christopher J. Schmidt	226
6	In pursuit of α4β2 nicotinic receptor partial agonists for smoking cessation: Carbon analogs of (−)-cytisine 2005 ·Bioorganic & Medicinal Chemistry Letters ·Jotham W. Coe,Michael G. Vetelino,(unknown),Michael Wirtz,Paige R. Brooks,Eric P. Arnold,Lorraine A. Lebel,Carol B. Fox,Steven B. Sands,Thomas I. Davis,David W. Schulz,Hans Rollema,F. David Tingley,Brian T. O’Neill	49
7	3,5-Bicyclic aryl piperidines: A novel class of α4β2 neuronal nicotinic receptor partial agonists for smoking cessation 2005 ·Bioorganic & Medicinal Chemistry Letters ·Jotham W. Coe,Paige R. Brooks,Michael Wirtz,(unknown),(unknown),Michael G. Vetelino,Eric P. Arnold,Lorraine A. Lebel,Carol B. Fox,F. David Tingley,David W. Schulz,Thomas I. Davis,Steven B. Sands,Robert S. Mansbach,Hans Rollema,Brian T. O’Neill	57
8	[3H]-(R)-NPTS, a radioligand for the type 1 glycine transporter 2003 ·Bioorganic & Medicinal Chemistry Letters ·John Lowe,Susan E. Drozda,Katherine Fisher,Christine A. Strick,Lorraine A. Lebel,Christopher Schmidt,(unknown),Kathleen S. Zandi	23
9	Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile 2001 ·European Journal of Pharmacology ·Anne W. Schmidt,Lorraine A. Lebel,Harry Howard,Stevin H. Zorn	230
10	5-[(3-Nitropyrid-2-yl)amino]indoles: Novel Serotonin Agonists with Selectivity for the 5-HT1D Receptor. Variation of the C3 Substituent on the Indole Template Leads to Increased 5-HT1D Receptor Selectivity 1994 ·Journal of Medicinal Chemistry ·John E. Macor,(unknown),Carol B. Fox,Lorraine A. Lebel,Michael E. Newman,Ronald J. Post,Kevin Ryan,Anne W. Schmidt,David W. Schulz,B. Kenneth Koe	27
11	Characterization of [³H]CP‐96,501 as a Selective Radioligand for the Serotonin 5‐HT_1B Receptor: Binding Studies in Rat Brain Membranes 1992 ·Journal of Neurochemistry ·B. Kenneth Koe,Lorraine A. Lebel,Carol B. Fox,John E. Macor	20
12	Synthesis and serotonergic pharmacology of the enantiomers of 3-[(N-methylpyrrolidin-2-yl)methyl]-5-methoxy-1H-indole: discovery of stereogenic differentiation in the aminoethyl side chain of the neurotransmitter serotonin 1992 ·Journal of Medicinal Chemistry ·John E. Macor,(unknown),Carol B. Fox,(unknown),B. Kenneth Koe,Lorraine A. Lebel,Jean Morrone,Kevin Ryan,Anne W. Schmidt	14
13	1-(2-Aminoethyl)-3-methyl-8,9-dihydropyrano[3,2-e]indole: a rotationally restricted phenolic analog of the neurotransmitter serotonin and agonist selective for serotonin (5-HT2-type) receptors 1992 ·Journal of Medicinal Chemistry ·John E. Macor,Carol B. Fox,(unknown),B. Kenneth Koe,Lorraine A. Lebel,Stevin H. Zorn	19
14	Structure-activity relationship of quinazolinedione inhibitors of calcium-independent phosphodiesterase 1991 ·Journal of Medicinal Chemistry ·John Lowe,Robert Archer,Douglas S. Chapin,(unknown),(unknown),Jeff Johnson,B. Kenneth Koe,Lorraine A. Lebel,Peter F. Moore	77
15	4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressantsbreakdown → 1990 ·Journal of Medicinal Chemistry ·Reinhard Sarges,Harry Howard,Ronald G. Browne,Lorraine A. Lebel,Patricia A. Seymour,B. Kenneth Koe	358
16	3-(1,2,5,6-Tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one: a potent and selective serotonin (5-HT1) agonist and rotationally restricted phenolic analog of 5-methoxy-3-(1,2,5,6-tetrahydropyrid-4-yl)indole 1990 ·Journal of Medicinal Chemistry* ·John E. Macor,Catherine A. Burkhart,James Heym,Jeffrey L. Ives,Lorraine A. Lebel,Michael E. Newman,J.A. Nielsen,Kevin Ryan,David W. Schulz	138
17	[3H] sertraline binding to rat brain membranes 1990 ·Psychopharmacology ·B. Kenneth Koe,Lorraine A. Lebel,W. M. WELCH	14
18	Sertraline potently displaces (+)-[3H]3-PPP binding to σ sites in rat brain 1989 ·European Journal of Pharmacology ·Anne W. Schmidt,Lorraine A. Lebel,B. Kenneth Koe,Thomas Seeger,James Heym	50
19	Sertraline, a selective inhibitor of serotonin uptake, induces subsensitivity of β-adrenoceptor system of rat brain 1987 ·European Journal of Pharmacology ·B. Kenneth Koe,(unknown),Lorraine A. Lebel,(unknown),(unknown)	32
20	Enhancement of benzodiazepine binding by methaqualone and related quinazolinones 1986 ·Drug Development Research ·B. Kenneth Koe,(unknown),(unknown),Lorraine A. Lebel,(unknown)	12

About Lorraine A. Lebel

Lorraine A. Lebel is a scholar working on Cellular and Molecular Neuroscience, Organic Chemistry and Biochemistry, having authored 42 papers that have together received 2.6k indexed citations. Recurring topics across this work include Receptor Mechanisms and Signaling (19 papers), Neuroscience and Neuropharmacology Research (13 papers) and Synthesis and Biological Evaluation (11 papers). The work is most often cited by research in Cellular and Molecular Neuroscience (824 citations), Pharmacology (533 citations) and Biological Psychiatry (68 citations). Lorraine A. Lebel has collaborated with scholars based in United States, Poland and United Kingdom. Frequent co-authors include Harry Howard, B. Kenneth Koe, Anne W. Schmidt, Stevin H. Zorn, David W. Schulz, Ronald G. Browne, Patricia A. Seymour, Reinhard Sarges, Leslie K. Chambers and F. David Tingley. Their work appears in journals such as Journal of Medicinal Chemistry, Journal of Neurochemistry and Journal of Pharmacology and Experimental Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact